source
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.BioPharma Dive · 20d ago↗ source
- FDA quietly pushes back deadline on electric shock banMassachusetts' biggest nursing strike ever, tackling the male loneliness epidemic, and other health news for Morning RoundsSTAT · 20d ago↗ source
- Opinion: The primary care crisis paradox“Solving the health crisis in the United States will require confronting things far harder than readjusting a fee schedule.”STAT · 20d ago↗ source